Detailed Narrative
Robust Q1 FY27 Financial Performance
Global Health Limited reported a strong Q1 FY27, with consolidated income growing 26% year-on-year to INR13,262 million. Reported EBITDA, including Noida, increased 23% year-on-year to INR3,153 million, achieving a margin of 23.8%. This performance was driven by robust patient volumes, improved realization, and sustained momentum across established hospitals, reflecting the strength of the operating platform.
Noida Hospital's Accelerated Ramp-up
Medanta Noida demonstrated significant progress in Q1 FY27, with its total income rising from INR525 million in Q4 FY26 to INR855 million. The EBITDA loss sharply declined from INR236 million in Q4 FY26 to just INR49 million in Q1 FY27. Management now expects Noida to achieve EBITDA breakeven earlier than previous expectations, highlighting the successful ramp-up of the facility.
Cluster-wise Operational Highlights
The company reclassified its hospitals into Cluster 1 (established) and Cluster 2 (developing). Cluster 1, comprising Gurugram, Indore, and Ranchi, reported INR7,715 million in revenue (10% YoY growth) and INR1,858 million in EBITDA (13% YoY growth), with a 24.1% margin. Cluster 2, including Lucknow, Patna, and Noida, saw total income grow 55% YoY to INR4,983 million, with EBITDA increasing 35% to INR1,272 million. Excluding Noida, Cluster 2 delivered 28% revenue growth and 40% EBITDA growth with a strong 32% margin.
Capacity Expansion and Future Projects
Medanta added 72 operational beds in Q1 FY27 (51 in Noida and 21 in Lucknow), bringing the total operational bed capacity to 3,737. The proposed Guwahati hospital project has been expanded to a 650-bed super specialty facility with an estimated project cost of INR9,700 million, an increase from earlier estimates due to revised building bylaws. The overall expansion pipeline now totals nearly 3,350 additional beds, providing a strong runway for long-term growth.
Volume Growth and Operational Efficiency
The network witnessed healthy growth in patient volumes, with inpatient volumes increasing 28% YoY and outpatient volumes growing 34% YoY. Occupied bed days increased by 21%, maintaining a network occupancy of 63%. Average revenue per occupied bed (ARPOB) grew 5% YoY to INR70,244, supported by a favorable case mix and increasing contribution from high acuity specialties. International patient revenue grew 23% YoY to INR782 million, and OPD pharmacy business revenue increased 51% YoY to INR609 million.
Capital Expenditure and Balance Sheet Strength
The company incurred INR1,610 million in capital expenditure during Q1 FY27, primarily for ongoing expansion projects like Guwahati and bed additions. Management emphasized a 'very low leverage' position, indicating a strong balance sheet capable of funding future growth initiatives. The focus remains on strategic investments in advanced technologies and clinical talent to support long-term value creation.